Bio-Path completes first dose cohort of BP1002 Phase 1/1b trial in AML; no dose-limiting toxicities

BIO-PATH HOLDINGS, INC.

First cohort (20 mg/m2) completed with no dose-limiting toxicities in 3 evaluable refractory/relapsed AML patients.
BP1002 uses RNAi to limit Bcl-2 protein production, offering potential treatment for venetoclax-resistant patients.
Treatment cycle: two doses per week for 4 weeks (8 doses over 28 days).
Phase 1b portion will assess BP1002 in combination with decitabine after monotherapy cohorts.
National PI is Dr. Gail Roboz, director of Clinical and Translational Leukemia Program at Weill Cornell.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.